INS and diabetic kidney disease: GLP1-RA treatment compared to placebo, the negative control, could demonstrate an ability to decrease UACR si, but GLP1-RA treatment compared to insulin therapy, the positive control, could demonstrate superiority in the treatment of DKD compared to current staples in the treatment of glycemic control and DKD.